This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2024-05-22), PureTech Health's share price is $2.85. PureTech Health's Median PS Value is $0.00. Therefore, PureTech Health's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for PureTech Health's Median PS Value or its related term are showing as below:
PTCHF's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.695 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
PureTech Health Median PS Value Historical Data
The historical data trend for PureTech Health's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PureTech Health's Median PS Value
For the Biotechnology subindustry, PureTech Health's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where PureTech Health's Price-to-Median-PS-Value falls into.
PureTech Health Median PS Value Calculation
PureTech Health's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (OTCPK:PTCHF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
PureTech Health's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.85
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health Median PS Value Related Terms
Thank you for viewing the detailed overview of PureTech Health's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
PureTech Health (PureTech Health) Business Description
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PTCHF has been successfully added to your 